2025
BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
Dubinsky M, Schreiber S, Matsuoka K, Jairath V, Al-Bawardy B, Pellanda P, Zhu B, Bleakman A, Redondo I, Owen C, Limdi J. BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB. Inflammatory Bowel Diseases 2025, 31: s62-s63. DOI: 10.1093/ibd/izae282.147.Peer-Reviewed Original ResearchNumerical rating scalePain numerical rating scaleModified Mayo scoreMultivariate linear regression analysisInflammatory Bowel Disease QuestionnaireUnivariate analysisUlcerative colitisMayo scorePrognostic variablesAnti-IL-23p19 antibodyBaseline characteristics of patientsAnti-IL-23p19Linear regression analysisPhase 3 trialRegression analysisCharacteristics of patientsUrgency Numeric Rating ScaleBristol Stool ScaleMultivariate regression analysisPost hoc analysisUnivariate analysis of associationPrognostic factorsDisease extentBaseline characteristicsMirikizumab
2014
Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C
Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, Colby CL, Canterbury K, Warner J, Therneau TM. Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. Mayo Clinic Proceedings 2014, 89: 595-601. PMID: 24661475, PMCID: PMC4160303, DOI: 10.1016/j.mayocp.2014.01.024.Peer-Reviewed Original ResearchConceptsRapid virologic responseChronic hepatitis CVirologic responseEarly virologic responseTriple therapyDual therapyHepatitis CP-IFNSustained virologic responseTreatment response categoriesTreatment-naive patientsPhase 3 trialRBV dose reductionPrior nonresponsePrior relapseCirrhosis statusProspective databaseViral hepatitisHemoglobin levelsAntiviral therapyWeek 4Dose reductionMean decreaseEligibility criteriaPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply